AACR Annual Meeting 2026
The next ADC generation showed its shape: bispecific and dual-payload constructs, new targets (MERTK, CDCP1, LRRC15, STn, integrin αvβ6, ALPP), and AI-nominated antigens, almost all carrying topoisomerase-I payloads.
- 01
Bispecific ADCs multiply
JS212 (EGFR/HER3, exatecan; ORR up to 45.5% in oesophageal cancer, first-in-human), ACR335 (cMET/EGFR with dual TOP1 + non-TOP1 payloads, DAR 4+4, phase 1 planned Q2 2026), and BH4601 (PD-L1/B7-H3 tetravalent, preclinical) were presented.
Source - 02
ZW191 (FRα, TOP1 payload) response in heavily pretreated ovarian and endometrial cancer
Zymeworks reported a 52% objective response rate in dose optimisation in heavily pretreated ovarian/endometrial patients with its hydrophilic-linker TOP1 ADC.
Source - 03
New ADC targets enter the clinic
5T4 (ACR246, 35% ORR, >90% disease control), Tissue Factor with TOP1 payload (XNW28012, phase 1/2 and 3), CLDN18.2 (XNW27011, phase 3 in gastric and pancreatic), LRRC15 (ZL-6201, TMALIN platform, tumour and CAF targeting), FGFR2b (3H-10000), Nectin-4 with belotecan-derived payload (MK-3120, distinct responder profile from enfortumab).
Source - 04
AI-nominated and microenvironment-directed ADC targets
DualityBio's DB-1329 (CDCP1) came from AI-driven multi-omics target identification; Inspirna's RGX-019-MMAE targets MERTK to deplete M2 macrophages without retinal toxicity; LaNova's LM-338 targets the STn glycan.
Source